Sachs Associates’ Post

View organization page for Sachs Associates, graphic

2,849 followers

Christoph joined Merck KGaA, Darmstadt, Germany in 2016, contributing across various fields including R&D and Digital Health, before transitioning to the Global Business Development & Alliance Management team. Currently, he serves as the Director Global Business Development & Licensing Oncology. With more than 10 years of experience in the pharmaceutical industry, Christoph has crafted partnering strategies and led negotiation teams for numerous transactions. He has directly worked on key deals for Merck KGaA, Darmstadt, Germany including the in-licensing of Abbisko Therapeutics' pimicotinib, and Inspirna’s ompenaclid, expanding Merck KGaA, Darmstadt, Germany’s oncology footprint in China and enhancing its colorectal cancer portfolio, as well as the in-licensing of Hengrui’s PARP1 DNA damage response inhibitor. Additionally, he successfully out-licensed the IL-12 fusion protein formerly known as NHS-IL12 to PDS Biotech. Christoph is a pharmacist, holding a PhD in Pharmaceutical Technology from the Ludwig- Maximilians-University of Munich, and an MBA from both the Kellogg School of Management, Northwestern University, and WHU Vallendar. Meet Dr. Christoph Korpus, MBA @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics